Buprenorphine + Naloxone Sublingual Films/Tablets Suppliers & Bulk Manufacturers
Available Forms: Sublingual Films/Tablets
Available Strengths: 2 mg buprenorphine / 0.5 mg naloxone, 8 mg / 2 mg
Reference Brands: Suboxone(US)
Category:
Analgesic
Buprenorphine + Naloxone sublingual films/tablets activate mu-opioid receptors, relieving pain and preventing withdrawal. Naloxone blocks opioid effects if injected, reducing misuse. Benefits include effective pain relief, lower overdose risk when used properly, and convenience of sublingual administration, promoting adherence and safety in opioid dependence and pain management.
Buprenorphine + Naloxone Sublingual Films/Tablets is available in Sublingual Films/Tablets
and strengths such as 2 mg buprenorphine / 0.5 mg naloxone, 8 mg / 2 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Buprenorphine + Naloxone Sublingual Films/Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Buprenorphine + Naloxone Sublingual Films/Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Buprenorphine + Naloxone sublingual films and tablets are approved in the EU and US primarily for opioid dependence treatment, with some off-label use for pain. In the US, brands like Suboxone are regulated by the FDA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the EU, approval by EMA involves comprehensive dossiers, clinical data, and pharmacovigilance plans. Due to abuse potential, strict prescribing controls and monitoring are enforced. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for buprenorphine + naloxone formulations, ensuring adherence to European and US standards for safe, effective opioid dependence management and pain therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing